checkAd

     524  0 Kommentare DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children - Seite 3

    DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

    Forward Looking Statements

    This press release contains forward-looking statements, including statements reflecting management's expectations for clinical development of our product candidates, future financial and operational performance and business outlook our research and development efforts and the commercial potential of our product candidates generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.  

    DBV Technologies Contact  
    Susanna Mesa
    Senior Vice President, Strategy
    +1 212-271-0861
    susanna.mesa@dbv-technologies.com
         
    Media Contacts  
    Erinn White, Centron PR
    Seite 3 von 4



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children - Seite 3 Press ReleaseMontrouge, France, June 27, 2016 DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children Company Expects to Report Topline Results for PEPITES in …